Drug Profile
Research programme: chimeric antigen receptor T-cell therapies - bluebird bio/Helixmith
Alternative Names: CAR T-cell therapies - bluebird bio/HelixmithLatest Information Update: 28 Jan 2020
Price :
$50
*
At a glance
- Originator ViroMed Co Ltd
- Developer bluebird bio
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours